The European Union has approved a new crown vaccine for conditional listing

Pharma.com December 22 - The European Medicines Agency on the 21st of the United States Pfizer Pharmaceutical Co., Ltd. and The German bio-new technology company jointly developed a new crown vaccine safety and effectiveness of a positive assessment, the European Commission subsequently approved the vaccine in the European Union conditional listing.
European Commission President Jean-Claude von der Leyen said in a statement that night that the European Union had decided to grant the vaccine a conditional license to sell and to enter the European Union market.
said the vaccine would be made available to all EU countries at the same time and under the same conditions.
in the coming days, the first vaccines will be shipped from Pfizer's production base in Belgium, where countries can begin vaccination work.
expects to deliver 200 million doses of the vaccine by September 2021.
European Medicines Agency head Aamer Cook said at a video news conference the same day, the FDA is based on clinical trial data of about 44,000 people to complete the evaluation of the vaccine, and ensure that its safety and ability and meet the necessary quality standards for people over 16 years of age to be vaccinated.
assessments will not stop there, and data on vaccine safety and ability will continue to be collected and analyzed.
the vaccine's effectiveness against the newly discovered mutant new coronavirus in the UK, Cook said there was no evidence that the vaccine was effective against the mutant virus.
the European Center for Disease Control and Prevention's weekly outbreak report, there are now more than 15.13 million new confirmed cases in the European Union, the European Economic Area and the United Kingdom, of which about 376,000 have died.
。